Can you explain current policy as it relates to biosimilars, including considerations that apply to interchangeability for anti-TNF biosimilars and product naming guidelines?

Can you explain current policy as it relates to biosimilars, including considerations that apply to interchangeability for anti-TNF biosimilars and product naming guidelines?

Can you explain current policy guidance as it relates to biosimilars, including considerations that do or do not apply to interchangeability for anti-TNF biosimilars and product naming guidelines? What is the threshold for interchangeability?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stanley Cohen, MD

Stanley Cohen, MD

Clinical Professor
Department of Internal Medicine
UT Southwestern Medical Center
Co-Director of the Division of Rheumatology
Presbyterian Hospital
Dallas, Texas